# US 2025/0082618 A1 · Dosing regimens using topical roflumilast compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082618 A1
- Document ID: US20250082618A1
- Status: Published application
- Kind: A1
- Application number: 18/827,222
- Filed: 2024-09-06
- Published: 2025-03-13
- Earliest claimed: 2023-09-07
- Assignees: Arcutis Biotherapeutics, Inc.
- Applicants: Arcutis Biotherapeutics, Inc.
- Inventors: David Reuben BERK; Patrick Burnett; David Chu
- Web page: https://patentgrep.com/patent/US20250082618A1

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 17/00: Drugs for dermatological disorders
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating a skin disorder or condition in a patient by topically administering to the patient a pharmaceutical composition comprising roflumilast. The methods of treatment include administering the roflumilast composition once a day for a period of time followed by administering the roflumilast composition twice weekly as a maintenance dosing regimen.

## Claims

### Claim 1

A method of treating a patient suffering from atopic dermatitis comprising:
topically administering to the patient a pharmaceutical composition comprising 0.05% or 0.15% roflumilast once a day for four weeks; and
topically administering to the patient the pharmaceutical composition twice a week,
wherein the twice weekly administration begins after the four weeks of once daily administration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for 124 days with twice weekly administration.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for fifty-two weeks with twice weekly administration.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient achieves a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one with once daily dosing.

### Claim 5 (depends on 4)

The method of claim 4, wherein the patient is administered the pharmaceutical composition twice weekly for two to fifty-two weeks.

### Claim 6 (depends on 4)

The method of claim 4, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for fifty-two weeks with twice weekly administration.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is a cream comprising a solvent, emulsifier, water, and moisturizer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the emulsifier comprises cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate, or a combination thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for 124 days with twice weekly administration.

### Claim 10 (depends on 7)

The method of claim 7, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for fifty-two weeks with twice weekly administration.

### Claim 11

A method of treating a patient suffering from atopic dermatitis comprising:
topically administering to the patient a pharmaceutical composition comprising 0.05% or 0.15% roflumilast once a day until the patient achieves a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero;
topically administering to the patient the pharmaceutical composition twice a week,
wherein the twice weekly administration begins after the once daily administration.

### Claim 12 (depends on 11)

The method of claim 11, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for 124 days with twice weekly administration.

### Claim 13 (depends on 11)

The method of claim 11, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for fifty-two weeks with twice weekly administration.

### Claim 14 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition is administered once daily for four weeks before beginning twice weekly administration.

### Claim 15 (depends on 14)

The method of claim 14, wherein the pharmaceutical composition is administered twice daily for two to fifty-two weeks.

### Claim 16 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition is a cream comprising a solvent, emulsifier, water, and moisturizer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for 124 days with twice weekly administration.

### Claim 18 (depends on 16)

The method of claim 16, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for fifty-two weeks with twice weekly administration.

### Claim 19 (depends on 16)

The method of claim 16, wherein the emulsifier comprises cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate, or a combination thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the patient maintains a Validated Investigator Global Assessment Scale for Atopic Dermatitis score of zero or one for fifty-two weeks with twice weekly administration.
